Aducanumab

Overview

4.5 out of 5 (33 Reviews)

Credits

1.00

Post Assessment Questions

5

Start Date

1 Sep 2023

Last Review Date

26 Feb 2024

Expiration Date

31 Aug 2026

Estimated Time To Finish

60 Minutes


 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

This activity focuses on the prescription of aducanumab, a groundbreaking amyloid ß-directed monoclonal antibody for the treatment of Alzheimer disease (AD). Granted accelerated approval by the United States Food and Drug Administration (FDA) in June 2021, aducanumab is the first AD treatment to receive formal regulatory clearance since 2003. The approval was based on clinical trial data demonstrating a reduction in amyloid plaques in treated individuals. 

This educational activity discusses key aspects such as indications, patient selection strategies, the mechanism of action, adverse event profiles, mandatory monitoring protocols, and contraindications for aducanumab use in AD management. The course emphasizes the pivotal role of interdisciplinary care teams in navigating these factors to deliver comprehensive care to individuals with AD, underlining the significance of close monitoring for potential adverse effects, notably amyloid-related imaging abnormalities (ARIA), which may necessitate dosing interruptions.


In late January, 2024 Biogen announced the discontinuation of aducanumab, citing a "reprioritazation" of the company's priorities in the AD space. Biogen explicitly disavowed any concerns about safety or efficacy underlying this decision. 

UAN: JA4008338-0000-23-6381-H01-P

Target Audience

This activity has been designed to meet the educational needs of physicians, physician associates, nurses, pharmacists, and nurse practitioners.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Differentiate the mechanism of action of aducanumab, especially in comparison to cholinesterase inhibitors and the NMDA-receptor antagonist, memantine. 

  • Select patients carefully and in accordance with criteria for appropriate use and guidelines for prescribing and monitoring. 

  • Identify the possible side effects of aducanumab, including criteria for discontinuation.

  • Collaborate with all members of the interprofessional team including primary care practitioners, neurologists, geriatric psychiatrists, geriatricians, neuroradiologists, pharmacists, and emergency department personnel to provide efficient, comprehensive, and coordinated care, plus capturing and responding to amyloid-related imaging abnormalities.

Pharmacy Activity Type:
Disease/Drug Therapy Related


Disclosures

StatPearls, LLC requires everyone who influences the content of an educational activity to disclose relevant financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflict(s) of interest have been mitigated. Hover over contributor names for financial disclosures. Others involved in planning this educational activity have no relevant financial relationships to disclose.

Commercial Support: This activity has received NO commercial support.

Continuing Education Accreditation Information

In support of improving patient care, StatPearls, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Pharmacists: StatPearls, LLC designates this activity for a maximum of 1.00 ACPE credit(s). (UAN: JA4008338-0000-23-6381-H01-P ). Pharmacists should only claim credit commensurate with the extent of their participation in the activity.

Please consult your professional licensing board for information on the applicability and acceptance of continuing education credit for this activity.

Method of Participation and Credit

  1. Register for the activity.    
  2. Review the target audience, learning objectives, and disclosure information.
  3. Study the educational content of the enduring material.
  4. Choose the best answer to each activity test question. To receive credit and a certificate, you must pass the test questions with a minimum score of 100%.
  5. Complete the post-activity assessment survey.

If you have concerns regarding the CE/CME system, please contact support@statpearls.com.

Disclaimer

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Faculty may discuss investigational products or off-label uses of products regulated by the FDA. Readers should verify all information before employing any therapies described in this educational activity.

The information provided for this activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The information presented does not necessarily reflect the views of StatPearls or any commercial supporters of educational activities on statpearls.com. StatPearls expressly disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through a participant's misunderstanding of the content.

Unapproved Uses of Drugs/Devices: In accordance with FDA requirements, the audience is advised that information presented in this continuing education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

Cancellation Policy: Please see the cancellation policy. StatPearls, LLC reserves the right to cancel any course due to unforeseen circumstances.

 

 
 

Reviews

Diane P. on 11/30/2021

MIA G. on 12/7/2021

Neelum A. on 12/13/2021

very pleased!

Sara E. on 12/18/2021

Michael N. on 1/19/2022

Ira on 3/22/2022

Amber F. on 4/12/2022

Peter M. on 8/17/2022

Cynthia L. on 8/29/2022

Good information

Kenneth R. on 10/29/2022

Sara E. on 11/15/2022

Ana R. on 11/21/2022

Michael P. on 11/29/2022

Andrew M. on 12/25/2022

JOSE P. on 2/8/2023

Rose F. on 2/28/2023

Amit P. on 4/17/2023

Arash S. on 4/21/2023

Alexander W. on 4/25/2023

Tariq C. on 5/30/2023

Daniel K. on 6/27/2023

Alejandro I. on 8/13/2023

Kira M. on 8/17/2023

Jennifer P. on 9/12/2023

Aimee G. on 11/27/2023

Mohamed E. on 12/6/2023

Theodore S. on 12/29/2023

Phillip T. on 12/31/2023

Kristen R. on 12/31/2023

Thomas M. on 1/14/2024

Joseph S. on 3/8/2024

Yashma P. on 3/18/2024

Margaret M. on 3/29/2024

Unlimited Pharmacist CE

Stay up to date on the latest medical knowledge with 6673 CE activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7924.5 hours of CE.

6 Month Unlimited Pharmacist CE

Access to all the Unlimited Pharmacist CE activities in all specialties.

$119 per half year per user

1 Year Unlimited Pharmacist CE

Access to all the Unlimited Pharmacist CE activities in all specialties.

$199 per 1 year per user